platoseedplatoseed
AI drug discovery platform for neurotherapeutics
We use AI and high-throughput mouse studies to discover therapeutics that modify neural activity in the brain. The initial focus is on epilepsies associated with autism and Parkinson’s disease with the potential to expand to any neurological disorder underlined by a dysfunction in neural activity. Our R&D is guided by AI models trained on high-density multimodal mouse data generated in-house. We are 3 Oxford-trained neuroscientists supported by an experienced SAB from Harvard, Science Corp (ex-Neuralink), EPFL, Meta, and UCL. In 1.5 months since landing in SF, we went from nothing to (1) opening and operating an animal lab in South SF, (2) obtaining a proof-of-concept in mice, (3) building a multimodal AI model that directs our screening approach and (4) submitting two provisional patents; all while utilizing less than 50% of our YC funding.
Exin Therapeutics is building a multimodal AI discovery platform for neurotherapeutics, focusing on predicting a drug candidate's potential across multiple neural disorders and enabling highly localized, multi-target discovery across genetic backgrounds and modalities.
An AI discovery platform that uses multimodal AI to predict a candidate's potential across multiple neural disorders simultaneously. It is agnostic to therapeutic modality, enabling discovery of next-generation neurotherapeutics with multi-target effects and highly localized action, accommodating diverse genetic backgrounds.
Who it’s for: Biotech/pharma companies and research organizations focused on neurotherapeutics and neural circuit disorders seeking AI-assisted target discovery and candidate evaluation
website mentions ongoing platform development and research team; no explicit funding or hiring details provided
Neuroscientist with a background in biochemistry and research on gene therapy, pancreatic cancer, and muscle physiology at institutions in Boston, Vienna, and Stockholm. Earned MSc in Neuroscience and PhD in Pharmacology at Oxford Uni, focusing on neurodevelopment and the effects of SSRI anti-depressants on early patterns of neural activity. Used neuroAI models at the Gatsby Unit (UCL) to study serotonin’s role in cognition. Currently developing gene therapies for neurological conditions.
Cofounder & COO @ Exin Therapeutics. Worked across analysis levels in bio – from molecules to complex behavior. Previously, I worked on retinal and circadian rhythm disorders, neurodevelopment, and systems and comp neuro, with a small stint in venture. Oxford MSc + PhD (on leave to build Exin).
Precise modulation of neural activity across neurological disorders.
Exin Therapeutics uses AI and high-throughput mouse studies to develop therapies addressing neurological and neuropsychiatric disorders by modulating brain circuits and neural activity. It aims to treat conditions such as epilepsy, ASD symptoms, and Parkinson’s disease, leveraging a multimodal AI model to prioritize and evaluate drug candidates for preclinical success.
Formerly “EI Therapeutics” · why startups rename →
Unsupervised Biological AI
The world's first AI-maximalist pharma company
